We report a 26-year-old female with AML, FAB classification M5 who was initially treated with induction therapy consisting of idarubicin and cytarabine followed by high-dose cytarabine and autologous peripheral blood progenitor cell (PBPC) transplant for consolidation. The patient remained in remission for 1 month post-PBPC transplant, when relapse was noted. Reinduction therapy with idarubicin, cytarabine and etoposide was unsuccessful, and the patient underwent an unrelated, two-antigen mismatched umbilical cord blood (UCB) transplant for salvage after melphalan plus total body irradiation. Complications post transplant included veno-occlusive disease, delayed engraftment, and acute grade III graft-versus-host disease (GVHD). The patient remains in remission 1 year post transplant. This study demonstrates the salvage capability of UCB transplantation for refractory leukemia and its potential use in adult patients. Keywords: umbilical cord blood transplant; refractory AML Bone marrow transplantation has been used successfully to treat a number of hematologic malignancies, including the acute leukemias. Both autologous and allogeneic transplants have been employed in this setting. The option of allogeneic transplants is often limited by the lack of an HLA-matched sibling donor, or the lack of an appropriate matched unrelated donor (MUD) in the National Marrow Donor Registry. Autologous transplants are limited by their high relapse rates which result from the lack of a graftversus-leukemia effect.
transplants, graft-versus-host disease has been noted to be less than that reported when matched sibling bone marrow is used as a source for hematopoietic progenitor cells. [3] [4] [5] Myeloid engraftment regularly occurs, with kinetics similar to that seen with MUD transplants, with only a few cases of primary graft failure reported. [4] [5] [6] Platelet recovery appears somewhat delayed with the median time to platelet recovery of у2 × 10 9 at 54 days and 56 days in two separate studies. One concern with the use of UCB has been that incidence of primary graft failure may increase when this procedure is performed for larger individuals due to the small numbers of hematopoietic stem cells administered. To date, most UCB transplants have been performed in children, and myeloid recovery appeared to correlate with the number of nucleated cells infused based upon recipient body weight in two trials, while this correlation was not seen in a third. 4, 5, 7 We currently report on the successful transplant and 1-year follow-up of a 52 kg 26-year-old woman who had previously failed an autologous bone marrow transplant for treatment of acute myelogenous leukemia. The patient underwent an unrelated, two-antigen mismatched umbilical cord blood transplant successfully, demonstrating the salvage potential and tolerability of this procedure in an adult patient.
Case history
The patient was initially diagnosed in February 1995 when she was noted to have a WBC of 180 000 at the time of delivery of her second child. A bone marrow biopsy revealed a hypercellular bone marrow with 50% myeloperoxidase-positive blasts. Cytogenetic evaluation revealed the tumor to be 53xx, hyperdiploid, and flow cytometric analysis revealed the tumor to be CD45 + , HLADR + , CD38 + , CD34
+ , CD33 + and CD13 + , all consistent with the diagnosis of AML, FAB classification M5. The patient underwent induction therapy with idarubicin and cytarabine (7 and 3) and obtained a complete response. She subsequently received two cycles of idarubicin and cytarabine and one cycle of high-dose cytarabine as consolidation. The patient completed induction/consolidation therapy without significant complications. Due to the lack of an HLA-identical sibling donor, she opted to proceed with an autologous peripheral blood stem cell transplant.
She underwent chemo-mobilization with cyclophosphamide plus G-CSF, and after two pheresis procedures a CD34 + cell dose of 3.11 × 10 6 /kg was obtained. The patient received busulfan and cytoxan followed by autologous peripheral blood progenitor cell infusion on 8 November 1995. Complications of this therapy included herpetic labialis, culture-negative fever, and grade 2 mucositis. She had neutrophil engraftment (an absolute neutrophil count of Ͼ500 mm 3 ) on day +15. Approximately 1 month later, fatigue, nasal congestion and a mildly productive cough developed. A peripheral blood smear revealed atypical myeloid precursors at various stages of maturation, and approximately 10% blasts. Repeat bone marrow biopsy and aspirate revealed a population of large mononuclear cells resembling her previous leukemia, thus establishing that relapse had occurred. In addition, cytogenetics revealed new abnormalities consisting of monosomy 7 and deletion of the short arm of chromosome 12.
She was reinduced with idarubicin, cytarabine and etoposide. A day 14 bone marrow post reinduction revealed 37% blasts; she experienced prolonged fever of uncertain etiology requiring treatment with multiple antibiotics plus amphotericin-B. Due to her small size (52 kg), inability to quickly identify a suitable donor through the National Marrow Donor Program, and the rapidity of the progression of her leukemia, we elected to proceed with an unrelated umbilical cord blood transplant as salvage. The conditioning regimen for the UCB transplant consisted of melphelan 45 mg/m 2 i.v. days −4 to −2, total body irradiation (13.5 CY given in 1.5 Gy fractions twice a day days −9 to −5), and ATGAM (30 mg/kg/day days −3 to −1). Graft-versushost disease prophylaxis included cyclosporine (1.5 mg/kg i.v. every 12 h) beginning day −1 and methotrexate 15 mg/m 2 given on day +1, and 10 mg/m 2 on days +3, +6 and +11. The patient received her umbilical cord blood transplant on 21 February 1996. UCB was procured from the New York UCB Bank. HLA typing was performed by serologic analysis for class I antigens and DNA analysis for class II antigens at the Shands Hospital HLA Lab at the University of Florida. She was noted to be an HLA mismatch at both A and B loci, and thus a two-antigen mismatched transplant ( Table 1 ). The total cell dose consisted of 6.12 × 10 8 nucleated cells for a dose of 1.11 × 10 7 nucleated cells per kg, 2.09 × 10 4 CFU-GM/kg after thawing. No CD34 + calculations were performed on the infused UCB product.
Results
Her post-transplant course was complicated by recurrent fever, grade 3 mucositis, GVHD and VOD. Veno-occlusive Table 1 HLA data on patient and umbilical cord blood donor disease of the liver was manifested by hepatomegaly, right upper quadrant abdominal pain, ascites and hyperbilirubinemia. No specific interventions were performed to treat the VOD other than fluid management. Improvement was seen prior to discharge, although other hepatic complications occurred later in the post-transplant course. Myeloid engraftment occurred with the absolute neutrophil count reaching 500/mm 3 on day +30. Platelet engraftment was delayed and more difficult to define due to recurrent GI hemorrhage which led to maintenance of the platelet count at Ͼ50 000/mm 3 . By day +145 the patient was able to maintain a platelet count of Ͼ50 000 mm 3 without subsequent transfusions. The hemoglobin level was maintained at 11 mg/dl and the patient required no packed red blood cell transfusions after day +137.
Infectious complications during the transplant course included recurrent fevers beginning during administration of the conditioning therapy. Blood cultures at that time were positive for coagulase-negative staphylococcal species and the patient was treated with vancomycin. Although fever persisted, no other blood cultures were noted to be positive during the initial admission. She was readmitted on day +73 with fever, decreased oral intake, and diarrhea. Workup revealed her to have adenovirus-positive stool cultures and she was treated empirically with i.v. antibiotics and general supportive care measures, with resolution of the diarrhea. Readmission was again required 1 week later due to recurrent fever and the development of hematochezia. Elevated SGOT, SGPT, bilirubin, alkaline phosphatase, and gamma GT were noted. Cultures were again obtained revealing persistent adenovirus in the stool. A flexible sigmoidoscopy was performed revealing changes most consistent with GVHD with no cytopathic viral effects noted. A CT scan revealed patchy areas of low attenuation, predominantly in the right lobe of the liver. A liver biopsy revealed multifocal polymorphonuclear aggregates (microabscesses), centrilobular sinusoidal distention, and normal bile ducts, all felt to be consistent with a viral process. All blood and biopsy cultures were found to be negative from both the flexible sigmoidoscopy and the liver biopsy. The patient was empirically started on ganciclovir with dramatic improvement noted in both the liver function tests and diarrhea.
GVHD occurred during week 4 following the unrelated UCB transplant. Palmar erythema, a waxing and waning skin rash, diarrhea, and hyperbilirubinemia were noted. Skin biopsy was nondiagnostic for GVHD. The hyperbilirubinemia was felt to be most consistent with VOD (as noted above). The diarrhea was noted to respond to loperamide, and no anti-GVH treatment was instituted at that time. Two weeks later she developed worsening diarrhea (Ͼ2 l of stool/day) and hematochezia. Flexible sigmoidoscopy revealed mucosal changes in the rectum and sigmoid colon consistent with GVHD. Methylprednisolone was administered at a dose of 2 mg/kg and within 2 days the rash resolved, the stool volume fell dramatically, and the bilirubin began to normalize. Over the ensuing weeks, a steroid taper was instituted with no evidence of GVHD flare. The patient was deemed to have grade 3 acute GVHD. At 1 year follow-up, the patient remains clinically in remission with normal blood counts. We have recommended a follow-up bone marrow biopsy and cytogenetics which have been refused by the patient. Indirect evidence of engraftment was seen by a switch in blood type from O+ pre-transplant to AB+ post-transplant. Currently, she has demonstrated complete recovery from all complications with a Karnofsky score of Ͼ90%.
Discussion
The use of UCB transplantation was able to salvage this patient with refractory AML, recurring shortly after a prior autologous bone marrow transplant. The initial ability to regain remission in this patient with refractory AML was possibly the result of the TBI containing conditioning regimen. Long-term remission, however, was probably multifactorial with a likely contribution from the graft-versusleukemia process. It has been suggested that cord blood T cells may be less able to mediate a graft-versus-leukemic process than those obtained from peripheral blood or bone marrow because the numbers of CD8 + T cells in UCB are lower. 8 Keever et al 9 indeed confirmed that cord blood cells may have reduced (but not absent) alloreactive potential but that LAK precursors with the potential to lyse leukemic cells are present in increased numbers in cord blood and might contribute to a GVL effect. Thus, a GVL effect is the most plausible explanation for the long-term, diseasefree survival noted in this patient.
The short procurement time to obtain UCB was also essential for success. If a donor had been sought via the National Marrow Donor program, a longer time would have elapsed (on average 3.5 months) before the cells became available for transplant, time that, in this instance, would have been prohibitively long. Thus, the short turn-around time may make the use of UCB preferable over matched unrelated bone marrow in a large number of cases where disease progression is rapid.
Myeloid engraftment was slower than that reported by Wagner et al 5 and Kurtzberg et al 4 who noted recovery with an ANC у500/mm 3 at 24 and 22 days respectively. In the Gluckman report which compiled data from 45 transplant centers around Europe for related and unrelated UCB transplants, the median recovery time of 30 days was similar to that seen in our patient. 7 Platelet recovery was also delayed, similar to the findings in all three above mentioned trials. One explanation may be the small numbers of nucleated cells administered per kg patient body weight. In both the Kurtzberg and Gluckman reports, total nucleated cell dose correlated with the speed of myeloid engraftment, while the Gluckman report went further to define a dose of less than 37 million nucleated cells per kilogram to correlate with delayed engraftment. A delay in platelet engraftment was further associated with a weight of Ͼ20 kg and with HLA identity (sibling vs unrelated donor source). Thus, cell dose appears to affect engraftment, especially in larger individuals, which would encompass an adult population.
In earlier reported trials there were very few larger patients in excess of 50 kg. The Wagner trial reported three patients of approximately 50 kg or greater. Of those patients, one died prior to engraftment, one achieved an ANC of у500 mm 3 on day 24, while the third did not achieve myeloid engraftment until day 53. In both patients where myeloid recovery was documented, platelet independence was not obtained at the time of last reported followup. In the Kurtzberg trial, two patients у50 kg were reported, and both achieved myeloid and platelet recovery, although time to engraftment was not specifically reported for each individual patient. A further review of the literature reveals an additional two patients у50 kg undergoing UCB transplantation. In the first, a case report by Laporte et al, 10 a 55 kg patient underwent a 5/6 unrelated transplant. Myeloid engraftment was noted to occur as early as day 23, although the patient was supported with filgrastim in the post-transplant recovery period. The second case also demonstrated rapid myeloid recovery, but was a haploidentical sibling UCB transplant. 11 Most recently, the Gluckman trial reported on 143 transplantations from both sibling and unrelated donor sources. In that trial, individual patient data were not reported, but as a group, 23 patients greater than 45 kg were presented. Weight and age as independent factors did not correlate with engraftment (except for platelets in the sibling group), but dose of cells clearly did. Table 2 reviews the published literature to date for patients у50 kg undergoing UCB transplantation. Overall, no significant generalizations can be made concerning UCB transplants for larger individuals due to the limited number of patients reported in the literature, and the variability in their transplant courses. Engraftment in our case does not appear to fall outside the range seen in other reports to date, although the small sample size limits conclusions.
Another way to evaluate the question of engraftment would be to compare CD34
+ cell dose or CFU-GM with recovery. Unfortunately, to date most trials have not reported CD34 + cell dose. In the Kurtzberg study, where CD34
+ dose was reported, platelet recovery did appear to correlate with CD34 + cell dose, but this trend did not reach statistical significance. In this case, no CD34
+ cell count was calculated prior to transplant. If a correlation between cell dose (nucleated or CD34
+ cells) and engraftment or graft failure is established, then broader application of this procedure to more adults would be limited. More adults will need to undergo UCB transplantation to evaluate this issue better.
The issue of graft-versus-host disease also remains a question when evaluating the toxicity of UCB transplantation. In the three large trials published to date, GVHD appeared to be less than that seen with matched unrelated transplants using bone marrow as a source for hematopoietic progenitor cells. 3, 4 In one study 3 of 21 evaluable patients, only two developed grade 3 GVHD, and nine grade 2 GVHD. In a second study, a slightly higher percentage of patients developed grades 2-4 GVHD with seven developing grade 2, and two developing grade 3. 4 This equated to a probability of developing grade 3 GVHD by day 100 of 0.11 ± 0.08 for the second study. In both UCB series, the grade of GVHD did not correlate with the degree of HLA disparity, and patients were reported to respond promptly to steroid therapy. In the third trial, acute GVHD was associated with HLA disparity among related transplants, and was 50% for mismatched patients compared to 9% for those who received HLA identical cord blood. 10 For patients receiving unrelated cord blood transplants the incidence of acute GVHD was 32% (grades II-IV), which is much lower than reported for unrelated bone marrow transplants. Data reported by Balduzzi et al 3 for unrelated transplantation using bone marrow in children, grades 2-4 GVHD was reported at 83% for patients with HLAmatched transplants, and 98% with HLA-mismatched transplants. When adult populations are evaluated, the incidence and severity of GVHD has also been regarded to be higher. Whether these low rates of GVHD seen in pediatric populations will hold for adults undergoing UCB transplantation remains to be seen.
In conclusion, the use of UCB in the adult transplant setting needs further evaluation. Issues of delayed engraftment, GVHD, and sample availability will all play a role in determining the broader application of this procedure in the future.
